Alzheimer's disease

[1]  K. Blennow,et al.  Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease , 2015, Alzheimer's & Dementia.

[2]  Lars Bäckman,et al.  A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial , 2015, The Lancet.

[3]  B. Hyman,et al.  APOEε2 is associated with milder clinical and pathological Alzheimer disease , 2015, Annals of neurology.

[4]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[5]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[6]  R. Sperling,et al.  Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. , 2015, JAMA neurology.

[7]  I. Abdollahpour,et al.  Which variable is the strongest adjusted predictor of quality of life in caregivers of patients with dementia? , 2015, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[8]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[9]  Philip S. Insel,et al.  Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. , 2015, Brain : a journal of neurology.

[10]  C. Rowe,et al.  Beta-amyloid imaging with florbetaben , 2015, Clinical and Translational Imaging.

[11]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[12]  E. Sinforiani,et al.  Quality of Life in Alzheimer Disease: A Comparison of Patients’ and Caregivers’ Points of View , 2015, Alzheimer disease and associated disorders.

[13]  J. Laks,et al.  Awareness of disease is different for cognitive and functional aspects in mild Alzheimer's disease: a one-year observation study. , 2014, Journal of Alzheimer's disease : JAD.

[14]  P. Snyder,et al.  APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease , 2014, Molecular Psychiatry.

[15]  Daniel A. Cohen,et al.  Pharmacotherapies for sleep disturbances in Alzheimer's disease. , 2015, The Cochrane database of systematic reviews.

[16]  J. Laks,et al.  Caregivers' quality of life in mild and moderate dementia. , 2014, Arquivos de neuro-psiquiatria.

[17]  K. Blennow,et al.  SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease , 2014, Molecular Neurodegeneration.

[18]  K. Blennow,et al.  CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival , 2014, Neurology.

[19]  Keith A. Johnson,et al.  Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. , 2014, JAMA neurology.

[20]  K. Blennow,et al.  Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. , 2014, JAMA neurology.

[21]  S. Gauthier,et al.  Developments in Tau PET Imaging , 2014, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[22]  R. Sperling,et al.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.

[23]  Kristine Yaffe,et al.  Potential for primary prevention of Alzheimer's disease: an analysis of population-based data , 2014, The Lancet Neurology.

[24]  Philip S. Insel,et al.  Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease , 2014, Annals of clinical and translational neurology.

[25]  Nick C Fox,et al.  Symptom onset in autosomal dominant Alzheimer disease , 2014, Neurology.

[26]  John Seibyl,et al.  Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[28]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[29]  R. Barker,et al.  The incidence of Parkinson's disease in the North-East of England. , 2014, Age and ageing.

[30]  David M. Shade,et al.  Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. , 2014, JAMA.

[31]  D. Harvey,et al.  The Independent Contributions of Cognitive Impairment and Neuropsychiatric Symptoms to Everyday Function in Older Adults , 2014, The Clinical neuropsychologist.

[32]  J. Cummings,et al.  Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial , 2014, The Lancet.

[33]  A. Roses,et al.  New applications of disease genetics and pharmacogenetics to drug development. , 2014, Current opinion in pharmacology.

[34]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[35]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[36]  Michael W. Weiner,et al.  The future of blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[37]  Michael H. Connors,et al.  Predictors of institutionalization in dementia: a three year longitudinal study. , 2014, Journal of Alzheimer's disease : JAD.

[38]  Harald Hampel,et al.  Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease , 2014, Neuropsychopharmacology.

[39]  G. Schellenberg,et al.  Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. , 2014, JAMA.

[40]  C. Rowe,et al.  Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.

[41]  Sarah A. Chau,et al.  Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial , 2013, International Psychogeriatrics.

[42]  Randall J Bateman,et al.  Dominantly Inherited Alzheimer Network: facilitating research and clinical trials , 2013, Alzheimer's Research & Therapy.

[43]  R. Green,et al.  Using AD biomarker research results for clinical care , 2013, Neurology.

[44]  Wiesje M. van der Flier,et al.  Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints , 2013, Alzheimer's & Dementia.

[45]  Christine Haberler,et al.  Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series , 2013, Acta Neuropathologica.

[46]  E. Siemers,et al.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.

[47]  M. Staufenbiel,et al.  Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein , 2013, Science Translational Medicine.

[48]  Richard J. Caselli,et al.  Ushering in the study and treatment of preclinical Alzheimer disease , 2013, Nature Reviews Neurology.

[49]  W. Rocca,et al.  Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. , 2013, JAMA neurology.

[50]  Leslie M. Shaw,et al.  Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI , 2013, Acta Neuropathologica.

[51]  Rusha Shah.  The role of nutrition and diet in Alzheimer disease: a systematic review. , 2013, Journal of the American Medical Directors Association.

[52]  C. Parsons,et al.  Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease , 2013, Neurotoxicity Research.

[53]  A. Fagan,et al.  Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Alzheimer's & Dementia.

[54]  A. Atri,et al.  Effectiveness of antidementia drugs in delaying Alzheimer's disease progression , 2013, Alzheimer's & Dementia.

[55]  N. Scott,et al.  Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in northeast Scotland: the PINE study. , 2013, Parkinsonism & related disorders.

[56]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[57]  P. Vemuri,et al.  Brain β-amyloid load approaches a plateau , 2013, Neurology.

[58]  Muriel Noetzli,et al.  Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease , 2013, Clinical Pharmacokinetics.

[59]  Carlo Caltagirone,et al.  A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[60]  H. Uylings,et al.  Neuropsychiatric symptoms in Alzheimer's disease and vascular dementia. , 2013, Journal of Alzheimer's disease : JAD.

[61]  Kewei Chen,et al.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.

[62]  Daniel Rueckert,et al.  Injury markers predict time to dementia in subjects with MCI and amyloid pathology , 2012, Neurology.

[63]  Paul Edison,et al.  A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[65]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[66]  K. Blennow,et al.  Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[67]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[68]  J. Gómez-Amor,et al.  Determinants of quality of life in Alzheimer's disease: perspective of patients, informal caregivers, and professional caregivers , 2012, International Psychogeriatrics.

[69]  J. Gunter,et al.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.

[70]  J. Galvin,et al.  Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease. , 2012, Clinical practice.

[71]  J. Cummings,et al.  Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[72]  O. Almeida,et al.  Quality of life in Alzheimer's disease: different factors associated with complementary ratings by patients and family carers , 2012, International Psychogeriatrics.

[73]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[74]  Cornelis J Stam,et al.  Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. , 2012, Journal of Alzheimer's disease : JAD.

[75]  Quincy M. Samus,et al.  Quality of life of community-residing persons with dementia based on self-rated and caregiver-rated measures , 2012, Quality of Life Research.

[76]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[77]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[78]  A. McKee,et al.  Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[79]  A. Thinnes,et al.  Effect of educational and supportive strategies on the ability of caregivers of people with dementia to maintain participation in that role. , 2011, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[80]  J. Villalpando,et al.  Management of end-stage dementia. , 2011, Primary care.

[81]  Charles D. Smith,et al.  Hippocampal sclerosis in advanced age: clinical and pathological features. , 2011, Brain : a journal of neurology.

[82]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[83]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[84]  B. Strooper,et al.  The role of G protein-coupled receptors in the pathology of Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[85]  J. Stockman.  Disclosure of APOE Genotype for Risk of Alzheimer's Disease , 2011 .

[86]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[87]  Marie-Louise H. Hansen,et al.  Generic and Disease-Specific Measures of Quality of Life in Patients with Mild Alzheimer’s Disease , 2010, Dementia and Geriatric Cognitive Disorders.

[88]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[89]  K. Blennow,et al.  CSF biomarkers predict a more malignant outcome in Alzheimer disease , 2010, Neurology.

[90]  K. Blennow,et al.  Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease , 2010, Acta Neuropathologica.

[91]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[92]  L. Schneider,et al.  Sertraline for the treatment of depression in Alzheimer disease. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[93]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[94]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[95]  P. Deyn,et al.  Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P , 2009, Neurochemistry International.

[96]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[97]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[98]  Randall J Bateman,et al.  A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system , 2009, Annals of neurology.

[99]  K. Blennow,et al.  Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype , 2009, Dementia and Geriatric Cognitive Disorders.

[100]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[101]  K. Blennow,et al.  The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. , 2008, Clinical chemistry.

[102]  D. Geschwind,et al.  Biochemical markers in persons with preclinical familial Alzheimer disease , 2008, Neurology.

[103]  Jeffrey Cummings,et al.  Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. , 2008, The Journal of clinical psychiatry.

[104]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[105]  Colin L. Masters,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA. Authors' reply , 2008 .

[106]  K. Chien,et al.  Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. , 2007, Clinical therapeutics.

[107]  K. Blennow,et al.  Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly , 2007, Dementia and Geriatric Cognitive Disorders.

[108]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[109]  K. Blennow,et al.  Cerebrospinal fluid β-amyloid 1–42 concentration may predict cognitive decline in older women , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[110]  D. Holtzman.  Role of apoE/Aβ interactions in the pathogenesis of Alzheimer’s disease and cerebral amyloid angiopathy , 2001, Journal of Molecular Neuroscience.

[111]  D. Holtzman.  In vivo effects of apoE and clusterin on amyloid-β metabolism and neuropathology , 2007, Journal of Molecular Neuroscience.

[112]  J. Wesson Ashford,et al.  APOE genotype effects on alzheimer’s disease onset and epidemiology , 2007, Journal of Molecular Neuroscience.

[113]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[114]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[115]  C. van Broeckhoven,et al.  Mean age‐of‐onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40 , 2006, Human mutation.

[116]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[117]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[118]  Philip S. Insel,et al.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[119]  E. Loveman,et al.  A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease , 2006, International journal of geriatric psychiatry.

[120]  E. Lonn.  Vitamin E Supplementation, Cardiovascular Events, and Cancer—Reply , 2005 .

[121]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[122]  A. Goate,et al.  Mutations in APP have independent effects on Aβ and CTFγ generation , 2004, Neurobiology of Disease.

[123]  Peter P. Zandi,et al.  Apolipoprotein E ϵ4 Count Affects Age at Onset of Alzheimer Disease,but Not Lifetime Susceptibility: The Cache County Study , 2004 .

[124]  Brian R Ott,et al.  Patient versus informant perspectives of Quality of Life in Mild Cognitive Impairment and Alzheimer's disease , 2004, International journal of geriatric psychiatry.

[125]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[126]  Bruce J Aronow,et al.  ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.

[127]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[128]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[129]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[130]  R. Nitsch,et al.  Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. , 2003, Archives of neurology.

[131]  H. Vanderstichele,et al.  Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias , 2003, Molecular Psychiatry.

[132]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[133]  K. Blennow,et al.  Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds , 2003, Dementia and Geriatric Cognitive Disorders.

[134]  D. Bennett,et al.  Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. , 2003, Archives of neurology.

[135]  D. Holtzman,et al.  Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer’s disease , 2002 .

[136]  Laura E. Gibbons,et al.  Assessing Quality of Life in Older Adults With Cognitive Impairment , 2002, Psychosomatic medicine.

[137]  Chester A. Mathis,et al.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. , 2002, Bioorganic & medicinal chemistry letters.

[138]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[139]  R. Mahley,et al.  Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[140]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[141]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[142]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[143]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[144]  S. Younkin,et al.  Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease , 2000 .

[145]  R Brookmeyer,et al.  Age-specific incidence rates of Alzheimer’s disease , 2000, Neurology.

[146]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[147]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .

[148]  S. Paul,et al.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[149]  B. Hyman,et al.  The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. , 1999, Brain : a journal of neurology.

[150]  A. Fagan,et al.  Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. , 1999, The Journal of clinical investigation.

[151]  M. Bullido,et al.  Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene , 1998, FEBS letters.

[152]  T. Wisniewski,et al.  Biology of Aβ Amyloid in Alzheimer's Disease , 1997, Neurobiology of Disease.

[153]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[154]  A. del Palacio,et al.  Changes in phenotypes of apolipoprotein E and apolipoprotein(a) in liver transplant recipients. , 1997, Clinical transplantation.

[155]  H. Braak,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[156]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[157]  S H Ferris,et al.  A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. , 1996, JAMA.

[158]  Allan I. Levey,et al.  Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.

[159]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[160]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[161]  K. Blennow,et al.  A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[162]  R. Mahley,et al.  Stable Expression and Secretion of Apolipoproteins E3 and E4 in Mouse Neuroblastoma Cells Produces Differential Effects on Neurite Outgrowth (*) , 1995, The Journal of Biological Chemistry.

[163]  E Brisch,et al.  The Inhibitory Effect of Apolipoprotein E4 on Neurite Outgrowth Is Associated with Microtubule Depolymerization (*) , 1995, The Journal of Biological Chemistry.

[164]  L A Beckett,et al.  Age-specific incidence of Alzheimer's disease in a community population. , 1995, JAMA.

[165]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[166]  R. Mahley,et al.  Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. , 1994, Science.

[167]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[168]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[169]  R B D'Agostino,et al.  Incidence of dementia and probable Alzheimer's disease in a general population , 1993, Neurology.

[170]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[171]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[172]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[173]  W. Spielmeyer.  Histopathologie des Nervensystems , 1922 .